DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2021 年 11 月 04 日 9:50 上午 - 2021 年 11 月 05 日 5:00 下午

(US Eastern Standard Time)

Horsham, PA 19044

Master Protocols and Complex Innovative Design

Innovating for Modernized Clinical Trials

Session 2: Decision Making for Master Protocols

Session Chair(s)

Robert A. Beckman, MD

Robert A. Beckman, MD

Professor of Oncology and of Biostatistics, Bioinformatics, and Biomathematics

Georgetown University Medical Center, United States

Zoran  Antonijevic, MSc

Zoran Antonijevic, MSc

Vice President, Statistical Consulting

Abond CRO Inc., United States

The session will present basic principles of decision analysis for optimization of clinical trials, programs and portfolios with an emphasis on efficiency. Example applications will include standard protocols and portfolios, but will also focus on master protocols. A perspective on this topic from Europe’s EU-Pearl Program will also be presented. Finally, the roles of patients and trial participants as decision makers will be discussed.

Learning Objective :
  • Understand key concepts related to decision making for clinical trials, master protocols, and portfolios
  • Apply selected aspects of decision making with emphasis on master protocols
  • Understand Europe’s EU PEARL program and approach to decision making in master protocols
  • Define the role of patients as decision makers

Speaker(s)

Zoran  Antonijevic, MSc

Decision Making in a Broader Context

Zoran Antonijevic, MSc

Abond CRO Inc., United States

Vice President, Statistical Consulting

Robert A. Beckman, MD

Speaker

Robert A. Beckman, MD

Georgetown University Medical Center, United States

Professor of Oncology and of Biostatistics, Bioinformatics, and Biomathematics

Martin  Posch, PhD

Speaker

Martin Posch, PhD

Medical University of Vienna, Austria

Professor

Gianna  McMillan, PhD

Speaker

Gianna McMillan, PhD

Loyola Marymount University, United States

Bioethics Institute, Associate Director

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。